Head-to-head · WeighScore
Näky vs Zealthy
The verdict
Näky takes it — 57.6/100 to 46.7/100.
Näky grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Näky is a LegitScript-approved telehealth platform offering compounded semaglutide and tirzepatide alongside an uncommon oral semaglutide drops product and a separate GLP-1 microdose program, plus NAD+ and…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Näky | Zealthy |
|---|---|---|
| WeighScore | 57.6/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #395 | #496 |
| Semaglutide | Not disclosed | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | Not disclosed | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #395 · C
Strengths
- LegitScript Approved (verifiable for benaky.com)
- Oral semaglutide drops as a distinct product line — uncommon among compounded GLP-1 brands
- Separate GLP-1 microdose program offered
- Adds NAD+ and Sermorelin for patients wanting a longevity stack
- 3-minute online assessment with a same-day treatment plan
Where it loses points
- Ongoing monthly pricing for compounded semaglutide and tirzepatide isn't shown until intake
- Oral semaglutide drops and microdose program pricing not disclosed
- Legal entity and state of incorporation not disclosed
- Pharmacy partner not named — only a generic 'USA-based FDA-regulated' claim
- States served not listed; pricing pages return 404s
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.